Gilenya


Natalizumab ( Tysabri ), a humanized monoclonal antibody, was approved by the Food and Drug Administration ( FDA ) in...


The FDA ( Food and Drug Administration ) warned that a case of definite progressive multifocal leukoencephalopathy ( PML )...


Multiple sclerosis ( MS ) is a chronic disabling disease of the central nervous system ( CNS ), affecting more...


The lack of prospective trial data comparing certain multiple sclerosis therapies could be addressed with observational research. Researchers have investigated outcomes...


New analyses of pooled data from the FREEDOMS and FREEDOMS II trials have shown the consistent efficacy of Gilenya (...


Fingolimod ( Gilenya ) has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. The...


Previous therapeutic strategies for multiple sclerosis ( MS ) include the non-selective suppression of systemic immunity ( immunosuppressive agents, such...


Starting Fingolimod ( Gilenya ) treatment, or re-starting Fingolimod after treatment interruption, results in transient decreases in heart rate. In...